The Company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The Company’s strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies with strong, supporting Phase I safety data.
Partnerships AstraZeneca: license to glucokinase activator IP in all indications (granted August 2024); Manoira (related party): joint development agreement evaluating the compounds in animal health
Indications
autoimmune disorders(Preclinical)
Status note Repurposed from a prior T2DM program (Phase 2 studies completed); company now repositioning in autoimmune disorders with preclinical work. No active clinical trial stated in excerpts.
AZD5658
Phase 1 · ActiveModality: small molecule (oral)
Target glucokinase
Partnerships AstraZeneca: licensed with AZD1656 (all indications)
Indications
not disclosed(Phase 1)
Status note Metabolite of AZD1656; completed single Phase 1 study in T2DM patients; no ongoing trial stated.
AZD5904
Phase 1 · ActiveModality: small molecule (oral)
Target myeloperoxidase (MPO)
Partnerships AstraZeneca: license for treatment, prevention and prophylaxis of idiopathic male infertility (granted August 2024)
Indications
idiopathic male infertility(Phase 1)
Status note Potent irreversible myeloperoxidase inhibitor; five Phase 1 studies completed. Business strategy is to generate preclinical data then seek third-party license deals; no active trial stated.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.